| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_2a819eda0adf22936a52362eeebb9fb4 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/B82Y5-00 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-6905
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-554
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-544
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-551
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-542
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-6911
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-6923
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-6929 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/B82Y5-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-69
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-55
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-54
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-127 |
| filingDate |
2019-11-18-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate |
2022-09-06-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_28b7adc7c68036a0042639eb949c50bc
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a35f4f387afb5d71d0027e4583ecd39b
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_60f6812d705487e6d3266e7f0612c6ab |
| publicationDate |
2022-09-06-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-11433143-B2 |
| titleOfInvention |
Nano-enabled immunotherapy in cancer |
| abstract |
In certain embodiments a platform technology for the facilitating immune therapy in the treatment of cancer is provided. In certain embodiments nanocarriers are provided that facilitate delivery of an IDO inhibitor in conjunction with an inducer of cell death (ICD-inducer). In certain embodiments the IDO inhibitor is conjugated to a component of a lipid bilayer forming a nanovesicle. In still another embodiment, methods and compositions are provided where an ICD-inducing agent (e.g., doxorubicin, oxaliplatin, mitoxantrone etc.) and an IDO pathway inhibitor (e.g., an IDO inhibitor-prodrug) are integrated into a nanocarrier (e.g. a lipid-bilayer (LB)-coated nanoparticle), that allows systemic delivery to orthotopic pancreatic cancer site. |
| priorityDate |
2017-05-18-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |